Danaher Partners With AstraZeneca to Support Precision Medicine

Danaher Corporation DHR recently partnered with AstraZeneca PLC AZN to develop and market novel diagnostic tools aimed at improving patient selection for precision medicine treatments.

Based in Cambridge, UK, AstraZeneca is a biopharmaceutical company that researches, develops, manufactures and commercializes innovative prescription medicines. The company works with primary and specialty care doctors through distributors and representative offices in the US, the UK, Europe and Asia.

Inside the Headlines

Precision medicines are targeted therapies that customize medical treatment according to a patient’s genetic makeup, environment and lifestyle. This approach helps doctors choose the best treatments for each patient.

Per the deal, the two companies will use the newly established Danaher Centers for Enabling Precision Medicine, created to simplify the full development process of diagnostic tools. The partnership’s first product will be developed by utilizing technologies from DHR’s subsidiary Leica Biosystems which is known for its digital pathology solutions. The collaboration will begin with a focus on AI-assisted algorithms and digital & computational pathology tools, that aim to improve diagnostic accuracy and patient selection for precision treatments.

Through this partnership, Danaher and AstraZeneca will create new diagnostic tools to help doctors figure out which patients will benefit the most from precision medicines. By making these tests available in labs around the world, the two companies aim to make precision medicine more accessible and improve treatment outcomes for patients worldwide.

DHR’s Zacks Rank & Price Performance

Danaher is benefiting from strong demand in its bioprocessing business, fueled by increased consumables orders from major pharmaceutical customers across North America, Europe, and Southeast Asia within the Biotechnology segment. Strength in the discovery and medical business also bodes well for the segment.

However, lower demand across academic and government end-markets has been weighing on Danaher’s protein consumables, flow cytometry and lab automation solutions businesses within the Life Sciences segment.

In the past three months, this Zacks Rank #3 (Hold) company’s shares have lost 7.4% compared with the industry’s 7% decline.

Image Source: Zacks Investment Research

Stocks to Consider

Some better-ranked companies from the same space are discussed below:

GeneDx Holdings Corp. WGS currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

WGS delivered a trailing four-quarter average earnings surprise of 145.8%. In the past 60 days, the Zacks Consensus Estimate for GeneDx Holdings’ 2025 earnings has increased 12.4%.

BrightSpring Health Services, Inc. BTSG currently carries a Zacks Rank #2 (Buy). BTSG delivered a trailing four-quarter average earnings surprise of 17.5%.

In the past 60 days, the Zacks Consensus Estimate for BrightSpring’s 2025 earnings has increased 39.7%.

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Source Zacks-com